BusinessProteon Therapeutics Receives FDA Breakthrough Therapy Designation for VonapanitaseBy Nasdaq OMXMay 10, 2017, 11:31 AM UTC
BusinessProteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical TrialBy Nasdaq OMXMay 2, 2017, 8:40 PM UTC
BusinessProteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4thBy Nasdaq OMXMay 1, 2017, 12:01 PM UTC
BusinessProteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22ndBy Nasdaq OMXMar 17, 2017, 11:55 AM UTC
BusinessProteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical TrialBy Nasdaq OMXMar 16, 2017, 11:15 AM UTC
BusinessNew Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary InterventionBy Nasdaq OMXMar 9, 2017, 1:00 PM UTC
BusinessProteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology MeetingBy Nasdaq OMXFeb 6, 2017, 10:00 PM UTC
BusinessProteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKDBy Nasdaq OMXDec 13, 2016, 12:00 PM UTC
